Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

714.47 -0.66 (-0.09%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 384,805
Open 712.30
Bid (Size) 694.00 (2)
Ask (Size) 729.00 (3)
Prev. Close 715.13
Today's Range 706.15 - 720.00
52wk Range 693.00 - 1,211.20
Shares Outstanding 91,779,465
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Are You Ready To Trade Biotech Stocks At The Cusp Of A Bear Market?
It’s not a bear market for biotech yet it just feels that way because recent trends are down and healthcare stocks are not a stabilizing force. 
Via Talk Markets
Topics ETFs Stocks / Equities
If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today
Via Benzinga

Performance

YTD
-21.05%
-21.05%
1 Month
-4.68%
-4.68%
3 Month
-30.71%
-30.71%
6 Month
-33.17%
-33.17%
1 Year
-15.90%
-15.90%

More News

Read More
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Via Benzinga
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
What 25 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
Via Benzinga
Regeneron Pharmaceuticals Unusual Options Activity
Via Benzinga
Regeneron Pharmaceuticals's Options: A Look at What the Big Money is Thinking
Via Benzinga
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron's Best-Selling Eye Drug Eylea's Higher Dose Formulation Meets Primary Goal In Another Form Of Retinal Disease Study
Via Benzinga
Exposures Product Safety
Stocks Slip As Strong November Retail Sales Raise Concerns Over 2025 Fed Rate Cuts
Via Benzinga
Topics Economy
Exposures Interest Rates
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Check Out What Whales Are Doing With REGN
Via Benzinga
28 Analysts Have This To Say About Regeneron Pharmaceuticals
Via Benzinga
EYLEA HD® (aflibercept) Injection 8 mg Phase 3 Trial Meets Primary Endpoint Showing Improved Vision with Extended Dosing Intervals in Patients with Macular Edema following Retinal Vein Occlusion
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?
Via Investor's Business Daily
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
Via Benzinga
It’s Been A Tough Month For Healthcare Stocks
Via Talk Markets
Topics ETFs Stocks / Equities
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
Not-So-Big Pharma
Via Talk Markets
FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
Via Benzinga
Exposures Product Safety
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.